Product Description
Mechanisms of Action: GABA Activator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Belgium | Chile | France | Hong Kong | Indonesia | Japan | Pakistan | Sri Lanka | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: PharPoint Research
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Epilepsy, Benign Neonatal|Seizures
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MI-5780 | P3 |
Terminated |
Epilepsy, Benign Neonatal |
2023-02-01 |
|
NCT03602118 | P3 |
Withdrawn |
Seizures |
2021-05-01 |
71% |